The Liquid Biopsy Global Market is Projected to Reach $8,730.4 Million by 2024
Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.
According to this analysis, the liquid biopsy global market is projected to reach $8,730.4 million by 2024. The liquid biopsy global market is segmented based on the biomarkers, applications, sample type, end-users and geography.
Biomarkers market is divided into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR.
The applications market is divided into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application market which is followed by prenatal testing (NIPT), however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at high double digit CAGR.
The oncology testing market is further divided based on type of cancer tested into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is further divided based on type of cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates the market in 2017, while early screening is expected to grow at strong CAGR.
The liquid biopsy sample market is divided into blood, urine and others where blood dominates the market in 2017 and is expected to maintain the position with strong CAGR growth from 2017 to 2024.
The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017. The hospitals segment is expected to show strong CAGR growth from 2017 to 2027.
The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW, where, North America dominates the market in 2017 followed by Europe with Asia-Pacific market expected to show highest growth from 2017 to 2024.
The report provides an in depth market analysis of the above mentioned segments across the following regions:
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Table of Contents
1 Executive Summary
Samples
LOADING...
Executive Summary
Liquid biopsy is a minimally invasive technology for the detection of molecular biomarkers without the need for invasive procedures. Circulating tumor cells (CTCs), Circulating free DNA (cfDNA), exosomes and others (microvesicles & apoptotic bodies) in the blood can help in diagnosing the disease condition and give clues about which treatments are most likely to work for that patient. The recent interest in nucleic acids present in blood and urine has opened up numerous new areas of investigation and new possibilities for molecular diagnosis.
In oncology, tumor-derived genetic changes, epigenetic alterations, and viral nucleic acids have been found in the plasma or serum of cancer patients. These findings have important implications for the detection, monitoring, and prognostication of many types of malignancies. In prenatal diagnosis, the discovery of fetal DNA in maternal plasma and serum has provided a non-invasive source of fetal genetic material for analysis. This development has important implications for the realization of non-invasive prenatal diagnosis and has provided new methods for the monitoring of pregnancy-associated disorders.
Plasma DNA technology has also found recent applications in the fields of organ transplantation, infectious agent detection and monitoring. Future areas of study include circulating RNA in plasma and the elucidation of the biology of release, clearance, and possible functionality of plasma nucleic acids.
According to this analysis, the liquid biopsy global market was estimated to reach $8,730.4 million by 2024. The factors driving the market are raising incidence of cancer, increasing preference for blood or urine based liquid biopsy, rising number of late pregnancies, technological advancements, increasing funding, agreements and collaborations. Whereas, factor such as high cost of tests with limited reimbursements and regulatory issues are restraining the market growth.
The liquid biopsy market is divided based on biomarkers, applications, sample, end-users and geography. The biomarkers market is further segmented into circulating tumor cells (CTCs), Cell-free DNA and exosomes and other, among them Cell-free DNA commanded the largest share and circulating tumor cells are project to grow at highest CAGR from 2017 to 2024. The applications market is segmented into oncology testing, prenatal non-invasive testing and transplantation diagnostics.
The oncology testing commanded the largest revenue of in 2017 and transplantation diagnostics is expected to show highest CAGR growth. The oncology testing market is further segmented based on type of cancer into lung, breast, colorectal, ovarian, prostate, melanoma and others. The breast cancer commanded the largest share in 2017 and lung cancer is expected to grow at double digit CAGR from 2017 to 2024. In segmentation based on cancer care, the application market consists of early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics commanded the largest revenue in 2017 where as recurrence monitoring is projected to grow at strong double digit CAGR from 2017 to 2024.
The liquid biopsy market by sample source is segmented into blood and urine & others. The blood based tests commanded largest share of the market in 2017 and is project to maintain its leading position from 2017 to 2024. The end-user market consist of Hospitals and academic & research institutes, here hospitals leads the market with revenue in 2017 and also projected to maintain the position till 2024.
Geographically, the market is segmented into North America, Europe, Asia-Pacific and RoW. The North America dominates the market with share in 2017 due to rising aging population, late pregnancies, preference for non-invasive tests where as Asia-Pacific is projected to be fastest growing market with high CAGR from 2017 to 2024 due to increasing affluence, awareness and increasing incidence of cancer in the region.
Technological advancements in liquid biopsy are expansion of applications beyond cancer diagnostics and monitoring to include other conditions such as cardiac health and infectious diseases and exploring of new sources for liquid biopsy such as miRNA, protein biomarkers and circulating MRNA. A paper based dip test called has been developed by scientists from Broad institute of MIT and Harvard, SHERLOCK, that make use of Cas13 CRISPR associated protein that bind to specific RNA to identify specific targets. This test is expected to detect tumor DNA in the near future.
The possibility of detection of health condition of an individual based on simple blood test has ignited imagination of scientific community and a flurry of activity has been unleashed. The absence of rigorous regulatory requirement as in case of a drug or a medical device also reduces the time to market for these tests which is attracting private investments. Some of the recent investments are funding of $40 million to MedGenome Labs Ltd by group of investors (HDFC, Sequoia, Sofina s.a. Zodiac Capital for expansion of clinical genomic testing of NIPT, Series C funding of DiaCarta in February 2018, to Support Company’s core XNA technology and expansion of diagnostic products. Biggest of them all investment of $900 million in GRAIL, Inc a spinoff of Illumina by Johnson & Johnson and Jeff Bezos of Amazon for development of ctDNA based tests.
Companies Mentioned
- Abbott Diagnostics
- Adaptive biotechnologies
- Admera health
- Affinity DNA
- Agena Bioscience, Inc
- Agilent (Multiplicom)
- AIOCARE Pvt Ltd (NIPTlab)
- Ambry Genetics
- Annoroad Gene Technology
- Apollo Center for Fetal Medicine
- ARUP Laboratories
- Beijing Berry and Kang Biotechnology Co., Ltd (Berry Genom
- BGI Diagnostics
- Bioarray SL
- Biocartis N.V.
- Biocept, Inc
- Biodesix, Inc
- BioMarcare technologies
- Bio-Rad Laboratories,
- Boreal Genomics
- Cancer Genetics, Inc
- CareDx, Inc
- CellMax Life
- Chronix Biomedical
- Circulogene theranostics
- Cooper Genomics (Recombine)
- Counsyl, Inc
- Cynvenio Biosystems, Inc
- Datar Genetics Limited
- Diacarta, Inc
- DiaDx
- DNA Forensics Laboratory
- DNA Labs India
- Eone-Diagnomics Genome Center (EDGC)
- Epic Sciences, Inc
- Epicgenomics AG
- Eurofins Scientific SE
- Exact Sciences Corporation
- Exosome Diagnostics, Inc
- Foundation Medicine, Inc
- Future health Biobank
- GATC Biotech AG
- GenePath Dx
- GeneTech
- Genetracer Biotech
- Genome Care
- Genomic Diagnostics
- Genomic Health, Inc
- Genoptix
- Gensignia Life Sciences, Inc.
- Guardant Health, Inc
- Igenomix
- Illumina, Inc
- Immucor
- ImpactLab Srl
- Inivata limited
- Integrated Diagnostics, Inc. (InDi Dx)
- Invitae Corporation
- LabCorp
- Lab Genomics
- Laboratory of Advanced Medicine (IvyGeneLabs)
- LCM Genect Srl
- LifeCell International Pvt. Ltd
- Liquid biotech USA, Inc
- MapMyGenome
- MDx Health
- Medgenome Labs Pvt. Ltd
- Menarini Silicon Biosystems Inc
- Metamark Genetics, Inc.
- Microgenomics Srl
- MiRXes pte Ltd
- Molecular MD
- Myriad Genetics,Inc
- Natera, Inc
- NeoGenomics Laboratories, Inc
- NIPD Genetics Public Company Ltd
- NxGen MDx LLC
- Oncocyte corporation
- OncoDNA S.A.
- OPKO Health, Inc (Bio-reference Laboratories) (Genpath Diagnos
- Pangaea oncology
- Pathway genomics
- Personal Genome Diagnostics, Inc
- PGL Labs, LLC (Pernonalized Genomics)
- Positive Bioscience
- Premaitha Health, PLC
- Progenity, Inc
- Provista Diagnostics, Inc
- ProXeom
- Qiagen N.V.
- Quest Diagnostics Incorporated
- Resolution Biosciences, Inc
- Roche Diagnostics
- SAGA Diagnostics
- Shanghai Genomatrix Medical Laboratory Co. Ltd.
- Siemens (Neo New Oncology GmbH)
- Sistemas Genomicos SL
- Strand Life Sciences Pvt Ltd
- SynapseDiagnostics
- Synlab International
- Sysmex Inostics GmbH
- TAI Diagnostics
- Trovagene, Inc
- Vanadis diagnostics (Perkin Elmer)
- Variantyx
- Vermillion, Inc (Aspira Labs)
- Victorian Clinical Genetics Services (VCGS)
- VolitionRX Limited
- Zer Laboratories, Ltd